Gonadorelin
PeptideThe medical score is 17 points above the community score because the scientific evidence for approved indications (hypogonadism, ovulation induction) is well documented [s8, s9], whereas the community evaluates gonadorelin primarily in the off-label TRT context, where disappointment over limited efficacy and downregulation effects is frequently reported [c3, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Gonadorelin is a synthetic GnRH analogue that acts as a full agonist at pituitary GnRH receptors, stimulating LH and FSH release via the Gq/11-phospholipase C signaling pathway. It is clinically used for hypogonadism, fertility disorders, and as a diagnostic tool for hypothalamic-pituitary axis function. Pulsatile administration preserves gonadotropic function, whereas continuous exposure leads to receptor desensitization and suppression. The overall benefit-risk profile is favorable when used under targeted medical supervision.
Description
Synthetic GnRH analogue that releases LH and FSH from the pituitary; used in hypogonadism, fertility disorders, and as a diagnostic agent [s1, s3].
Gonadorelin is a synthetic decapeptide structurally identical to endogenous gonadotropin-releasing hormone (GnRH) from the hypothalamus. It consists of the amino acid sequence Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly and binds with high affinity to GnRH receptors on gonadotrophs of the adenohypophysis [s3, s4]. With pulsatile administration (every 90–120 minutes), gonadorelin stimulates the physiological release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate gonadal function (testosterone production, spermatogenesis, ovulation) [s1, s3, s5]. With continuous administration—in contrast to pulsatile—downregulation of GnRH receptors occurs, with consequent suppression of the pituitary-gonadal axis [s4, s6]. Approved medical indications include: - Diagnostics of the hypothalamic-pituitary axis (GnRH stimulation test) [s1, s7] - Hypothalamic amenorrhoea and ovulation induction [s7] - Hypogonadotropic hypogonadism (e.g., Kallmann syndrome) [s5, s8] - Support of luteal function after ovulation [s2] In the biohacking and bodybuilding community, gonadorelin is increasingly used off-label as adjunct therapy to testosterone replacement therapy (TRT) to preserve testicular volume and endogenous testosterone production [c1, c2]. This application is not supported by sufficient RCT data [c3]. The half-life is 2–40 minutes, which explains the necessity of pulsatile infusion or very frequent injections [s7].
Legal Status (DE)
{'source_ids': ['s1', 's2', 's20', 's21'], 'source_upgrade_note': 'Official BfArM page on prescription requirements [s20] and consolidated AMVV legal basis on gesetze-im-internet.de [s21] added as Grade-A regulatory sources. Specific gonadorelin approval entry on PharmNet.Bund (database of approved medicinal products) recommended as further reference. Note: Gonadorelin is no longer actively marketed as a finished medicinal product in Germany (Lutrelef/Ferring); approval status to be verified via PharmNet.Bund or EMA database. '}
Mechanism of Action
Gonadorelin acts as a full agonist at the GnRH receptor (GnRHR), a G protein-coupled receptor (Gq/11 protein) on the surface of gonadotropic cells in the anterior pituitary [s3, s4]. Binding activates phospholipase C, leading to the formation of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release; DAG activates protein kinase C. This results in exocytosis of secretory vesicles containing LH and FSH [s3]. The frequency of GnRH pulses determines the LH-to-FSH ratio: rapid pulses (every 60–90 min) preferentially promote LH secretion and LH gene transcription; slow pulses (every 120+ min) favour FSH [s5]. With continuous (non-pulsatile) exposure, receptor internalisation and downregulation (desensitisation) occur, suppressing LH/FSH release within 10–14 days—the same principle exploited by GnRH agonists (leuprorelin, buserelin) for hormonal blockade [s4, s6]. LH stimulates testosterone synthesis in the Leydig cells of the testes; FSH activates Sertoli cells and is essential for spermatogenesis [s3, s5]. In women, LH stimulates ovulation and progesterone production in the corpus luteum; FSH promotes follicular maturation [s3].
Dosing
Allgemein
- Dose
- Frequency
- 1× täglich
- Route
- oral
- With food
- optional
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| OHSS | gelegentlich | leicht |
Contraindications
Gonadorelin can stimulate the gonadotropin axis and is contraindicated in existing pregnancy, except in clearly defined exceptions [s2, s10].
Conditions that may be exacerbated by hormonal stimulation constitute a contraindication [s2].
Allergic reactions up to anaphylaxis have been reported [s10].
In impaired hepatic or renal function, the effect of gonadorelin at the same dose may be prolonged and enhanced [s2].
Pharmacological antagonism or additive downregulation effect on the pituitary-gonadal axis [s4, s6].
Interactions
Synergistic
Kisspeptin physiologically stimulates endogenous GnRH secretion via kisspeptin receptors (Kiss1R) on hypothalamic GnRH neurons, such that combined administration with exogenous gonadorelin can result in additive or synergistic stimulation of LH and FSH release.
Enclomiphene, as a selective estrogen receptor antagonist, blocks negative hypothalamic feedback by estrogens, thereby increasing endogenous GnRH pulsatility and potentially enhancing the effect of exogenously administered gonadorelin on pituitary gonadotropin release.
Ashwagandha increases endogenous GnRH release in the hypothalamus while simultaneously lowering cortisol, which inhibits LH production. In combination with gonadorelin, additive stimulation of the HPG axis may occur.
Gonadorelin acts upstream at the pituitary and stimulates natural LH/FSH release, while HCG acts downstream by directly mimicking LH receptors on Leydig cells. A combination can cover the entire HPG axis and is clinically established in TRT adjunct therapy for fertility preservation.
DIM modulates estrogen metabolism and reduces negative estrogen feedback on the hypothalamus. In combination with gonadorelin, HPG axis stimulation could be enhanced through reduced estrogenic feedback.
Fenugreek contains furostanol saponins that may support LH release and testosterone production. In combination with gonadorelin, additive stimulation of the HPG axis at multiple levels is mechanistically plausible.
Caution
DHEA is peripherally metabolized to estrogens and androgens, which through negative feedback at the hypothalamus and pituitary can attenuate the GnRH or gonadotropin response to gonadorelin, potentially resulting in altered or diminished LH/FSH secretion.
Both peptides act at the pituitary – gonadorelin at GnRH receptors, CJC-1295 at GHRH receptors. Simultaneous use taxes pituitary secretory capacity and could lead to unpredictable hormonal shifts. Clinical data on the combination are lacking.
Ipamorelin stimulates GH release from the pituitary via the ghrelin receptor. Concurrent administration with gonadorelin means multiple pituitary stimulations. Clinical interaction data are lacking; the risk of receptor desensitization or hormonal imbalance cannot be excluded.
Studies
Tier A — High Evidence
Tier B — Moderate Evidence
Community Evidence
Top reported benefits
- Preservation of testicular volume during TRT
- Subjectively improved well-being and libido
- Perceived support of endogenous testosterone production
- More practical alternative to HCG (easier storage)
Top reported issues
- Loss of efficacy with daily use (downregulation)
- Many users report no noticeable difference compared to untreated TRT
- Short half-life as a practical issue
- HCG is frequently rated as more effective by experienced users
Several users report that gonadorelin loses efficacy within 1–2 weeks when administered concurrently with testosterone (downregulation), consistent with the pharmacological mechanism [s4, s6, c3]. Significant concerns exist regarding the quality and purity of gonadorelin from non-pharmaceutical sources [c2]. The evidence base for off-label use as a TRT adjunct is considered insufficient [c2, c3].
Scientific Sources
- Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome
Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R (2003). Cochrane Database of Systematic ReviewsA - Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort
Trofimova T, Lizneva D, Engmann L, Podfigurna A, Meczekalski B, Yuen T, Zaidi M (2022). Journal of Assisted Reproduction and GeneticsBDOI - The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men
Zhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z (2019). American Journal of Men's HealthBDOI - Gonadorelin: Uses, Interactions, Mechanism of Action
DrugBank Online (2024). DrugBankBLink - Gonadorelin: Wirkung, Anwendung und mögliche Nebenwirkungen
Pharmaphant Redaktion (2024). Pharmaphant.deCLink - Gonadorelin: Indications, Side Effects, Warnings
Drugs.com Editorial Staff (2024). Drugs.comCLink - Current and future applications of GnRH, kisspeptin and neurokinin B analogues
Jayasena CN, Abbara A, Dhillo WS, et al. (2014). Nature Reviews EndocrinologyBPMID:23797727DOI - Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
Jayasena CN, Comninos AN, De Silva A, et al. (2015). Journal of Clinical Endocrinology & Metabolism / PMCAPMID:26046963DOI - Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy
["Hsieh TC","Pastuszak AW","Hwang K","Lipshultz LI"] (2013). Journal of UrologyCPMID:23260875DOI - Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis
["Gong C","Li Y","Liu Y","et al."] (2020). World Journal of UrologyCPMID:32777865DOI - Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism
["Huang K","et al."] (2017). Asian Journal of AndrologyCPMID:28051040DOI - Effect and safety of pulsatile GnRH therapy for male congenital hypogonadotropic hypogonadism
["Ke Z","et al."] (2024). Zhonghua Yi Xue Za Zhi [Chinese Medical Journal]CPMID:39210488DOI - Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome
["Bayram N","van Wely M","van der Veen F"] (2004). Cochrane Database of Systematic ReviewsCPMID:14973957DOI - Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH
["Erel CT","Senturk LM","Inan D","Ertungealp E"] (1996). International Journal of Gynaecology and ObstetricsCPMID:8692506DOI - Gonadorelin - Anwendung, Wirkung, Nebenwirkungen
Gelbe Liste Pharmaindex (2024). Gelbe ListeBLink - Verschreibungspflicht von Arzneimitteln – Sachverständigen-Ausschuss nach § 53 Abs. 2 AMG; Verordnung über die Verschreibungspflicht von Arzneimitteln (AMVV) § 1 i.V.m. Anlage 1
["BfArM – Bundesinstitut für Arzneimittel und Medizinprodukte"] (2024). CLink - Verordnung über die Verschreibungspflicht von Arzneimitteln (AMVV) – Konsolidierte Fassung
["Bundesministerium für Gesundheit / Bundesministerium der Justiz"] (2023). CLink - Neurokinin B stimulates GnRH release in the male monkey (Macaca mulatta) and is colocalized with kisspeptin in the arcuate nucleus
["Ramaswamy S","Seminara SB","Ali B","Ciofi P","Amin NA","Plant TM"] (2010). EndocrinologyCPMID:20685874DOI - Factrel (gonadorelin hydrochloride) for injection — Prescribing Information
["U.S. National Library of Medicine – DailyMed"] (2010). CLink - Physiology, Gonadotropin-Releasing Hormone
Krsmanovic LZ, Hu L, Leung PK, et al. (2023). StatPearls, NCBI BookshelfBPMID:32119418 - Gonadotropin Releasing Hormone (GnRH) Analogues
LiverTox Editorial Staff (2023). LiverTox, NCBI BookshelfBLink - Gonadoliberin (GnRH)
Wikipedia-Autoren (2024). Wikipedia DECLink - Gonadotropin-releasing hormone agonist
Wikipedia Contributors (2024). Wikipedia ENCLink - Gonadorelin
Wikipedia Contributors (2024). Wikipedia ENCLink - The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men
Zhang L, Cai K, Wang Y, et al. (2019). American Journal of Men's Health / PMCBPMID:31547724DOI - Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study
Jiang X, Feng Y, Zhang Y, et al. (2025). Translational Andrology and UrologyBDOI
Community Sources
Storage
Unopened
Lyophilised powder: Store at 2–8 °C (refrigerator), protect from light; room temperature storage possible for a limited period according to manufacturer.
Opened
Reconstituted solution: Use immediately or store at 2–8 °C for a maximum of 24 hours. Do not freeze.
Notes
Gonadorelin is a sensitive peptide; contamination and improper storage can lead to degradation. Follow the respective manufacturer's instructions.